Trials / Completed
CompletedNCT05913440
HER2-low Unresectable and/or Metastatic Breast Cancer in Russia
A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Low Unresectable and/or Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,669 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Planned study population consists of approximately 3,150 adult patients with HER2-negative (IHC 0, + or IHC2+/ISH-) unresectable or metastatic BC enrolled to the study in order to obtain approximately 2,000 patients with confirmed HER2 low status (IHC1+ or IHC2+/ISH ).
Conditions
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2025-03-14
- Completion
- 2025-03-14
- First posted
- 2023-06-22
- Last updated
- 2026-03-12
Locations
40 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05913440. Inclusion in this directory is not an endorsement.